Andrew Messali

562 total citations
18 papers, 407 citations indexed

About

Andrew Messali is a scholar working on Economics and Econometrics, Psychiatry and Mental health and Pathology and Forensic Medicine. According to data from OpenAlex, Andrew Messali has authored 18 papers receiving a total of 407 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Economics and Econometrics, 4 papers in Psychiatry and Mental health and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Andrew Messali's work include Health Systems, Economic Evaluations, Quality of Life (6 papers), Migraine and Headache Studies (3 papers) and Stroke Rehabilitation and Recovery (2 papers). Andrew Messali is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (6 papers), Migraine and Headache Studies (3 papers) and Stroke Rehabilitation and Recovery (2 papers). Andrew Messali collaborates with scholars based in United States, United Kingdom and Japan. Andrew Messali's co-authors include Joel W. Hay, Peter J. Goadsby, Andrew Blumenfeld, Richard B. Lipton, Dawn C. Buse, Sepideh F. Varon, Michael E. Stokes, Shashidhar Kori, Lisa Bloudek and Dana P. Goldman and has published in prestigious journals such as Blood, PLoS ONE and Neuro-Oncology.

In The Last Decade

Andrew Messali

17 papers receiving 399 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew Messali United States 11 186 127 53 48 47 18 407
Deepan Dalal United States 11 233 1.3× 107 0.8× 45 0.8× 20 0.4× 33 0.7× 23 485
Barry Hendin United States 9 152 0.8× 249 2.0× 30 0.6× 55 1.1× 62 1.3× 22 680
H. C. M. Haanen Netherlands 10 109 0.6× 99 0.8× 19 0.4× 82 1.7× 34 0.7× 13 851
Kristian Stengaard‐Pedersen Denmark 14 92 0.5× 209 1.6× 26 0.5× 20 0.4× 44 0.9× 26 604
Haşim Çakırbay Türkiye 12 138 0.7× 47 0.4× 40 0.8× 16 0.3× 35 0.7× 30 492
P J Barendregt Netherlands 13 105 0.6× 66 0.5× 11 0.2× 46 1.0× 203 4.3× 17 582
Tyler Knight United States 13 89 0.5× 194 1.5× 36 0.7× 6 0.1× 28 0.6× 29 571
Karen Lien Canada 14 53 0.3× 20 0.2× 90 1.7× 33 0.7× 26 0.6× 20 446
Mehmet Şahin Türkiye 13 64 0.3× 37 0.3× 85 1.6× 11 0.2× 59 1.3× 33 478
Ioannis Papadopoulos Greece 12 62 0.3× 40 0.3× 39 0.7× 64 1.3× 60 1.3× 25 502

Countries citing papers authored by Andrew Messali

Since Specialization
Citations

This map shows the geographic impact of Andrew Messali's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Messali with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Messali more than expected).

Fields of papers citing papers by Andrew Messali

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Messali. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Messali. The network helps show where Andrew Messali may publish in the future.

Co-authorship network of co-authors of Andrew Messali

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Messali. A scholar is included among the top collaborators of Andrew Messali based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Messali. Andrew Messali is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Lyons, Genevieve, et al.. (2025). HPR145 Medicare Spending on Orphan Drugs With Single and Multiple Rare Disease Indications. Value in Health. 28(6). S219–S219.
2.
Piatek, Caroline, Jong Wook Lee, Morag Griffin, et al.. (2024). Danicopan As Add-on Therapy to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Patient-Reported Outcomes from the Phase 3 ALPHA Trial. Blood. 144(Supplement 1). 2692–2692. 1 indexed citations
3.
Kishnani, Priya S., Gabriel Ángel Martos‐Moreno, Agnès Linglart, et al.. (2024). Effectiveness of asfotase alfa for treatment of adults with hypophosphatasia: results from a global registry. Orphanet Journal of Rare Diseases. 19(1). 109–109. 16 indexed citations
4.
5.
Ng‐Mak, Daisy, et al.. (2019). Hospitalization risk in patients with schizophrenia treated with dose-equivalent antipsychotics.. PubMed. 25(14 Suppl). S279–S286. 3 indexed citations
6.
7.
Li, Nanxin, Keith A. Betts, Andrew Messali, Martha Skup, & Vishvas Garg. (2017). Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany. Clinical Therapeutics. 39(8). 1618–1627. 10 indexed citations
8.
Mu, Fan, et al.. (2016). Real-World Costs of Ischemic Stroke by Discharge Status. Value in Health. 19(3). A46–A46. 1 indexed citations
9.
Harrington, Rachel, Edward Lee, Hongbo Yang, et al.. (2016). Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis. Advances in Therapy. 34(1). 207–220. 27 indexed citations
10.
Agus, David B., Étienne Gaudette, Dana P. Goldman, & Andrew Messali. (2016). The Long-Term Benefits of Increased Aspirin Use by At-Risk Americans Aged 50 and Older. PLoS ONE. 11(11). e0166103–e0166103. 9 indexed citations
11.
Mu, Fan, et al.. (2016). Real-world costs of ischemic stroke by discharge status. Current Medical Research and Opinion. 33(2). 371–378. 24 indexed citations
12.
Messali, Andrew, Andrew Blumenfeld, Peter J. Goadsby, et al.. (2016). Direct and Indirect Costs of Chronic and Episodic Migraine in the United States: A Web‐Based Survey. Headache The Journal of Head and Face Pain. 56(2). 306–322. 143 indexed citations
13.
Gaudette, Étienne, Dana P. Goldman, Andrew Messali, & Neeraj Sood. (2015). Do Statins Reduce the Health and Health Care Costs of Obesity?. PharmacoEconomics. 33(7). 723–734. 14 indexed citations
14.
Messali, Andrew, et al.. (2014). A Review of the Economic Burden of Glioblastoma and the Cost Effectiveness of Pharmacologic Treatments. PharmacoEconomics. 32(12). 1201–1212. 42 indexed citations
15.
Messali, Andrew, et al.. (2014). Health Care Resource Utilization Following Initiation of a Triptan: A Retrospective Claims Analysis. Journal of Managed Care Pharmacy. 20(4). 368–375. 7 indexed citations
16.
Messali, Andrew, Mo Yang, Patrick Gillard, et al.. (2014). Treatment Persistence and Switching in Triptan Users: A Systematic Literature Review. Headache The Journal of Head and Face Pain. 54(7). 1120–1130. 39 indexed citations
17.
Hay, Joel W., et al.. (2013). Cost Effectiveness of Moderate to Severe Psoriasis Therapy with Etanercept and Ustekinumab in the United States. PharmacoEconomics. 31(9). 823–839. 21 indexed citations
18.
Messali, Andrew, et al.. (2013). The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States. Neuro-Oncology. 15(11). 1532–1542. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Deepan Dalal Breakdown of academic impact, for papers by Barry Hendin Breakdown of academic impact, for papers by H. C. M. Haanen Breakdown of academic impact, for papers by Kristian Stengaard‐Pedersen Breakdown of academic impact, for papers by Haşim Çakırbay Breakdown of academic impact, for papers by P J Barendregt Breakdown of academic impact, for papers by Tyler Knight Breakdown of academic impact, for papers by Karen Lien Breakdown of academic impact, for papers by Mehmet Şahin Breakdown of academic impact, for papers by Ioannis Papadopoulos
Rankless by CCL
2026